Site icon pharmaceutical daily

Global Subcutaneous Drug Delivery Market to Surpass US$ 9,111.6 Million by 2027, Says Coherent Market Insights

SEATTLE–(BUSINESS WIRE)–#DrugDelivery–According to Coherent Market Insights, the global subcutaneous drug delivery market is estimated to be valued at US$ 9,111.6 million in 2020 and is expected to exhibit a CAGR of 9.7% over the forecast period (2020-2027).

Key Trends and Analysis:

Increasing number of product approvals by regulatory authorities for the treatment of cancer is expected to drive growth of the subcutaneous drug delivery market. For instance, in February 2019, Genentech, a member of the Roche Group, received the U.S. Food and Drug Administration (FDA) approval for Herceptin Hylecta (trastuzumab and hyaluronidase-oysk), a subcutaneous injection, for treating patients with HER2-positive early breast cancer. In October 2019, AstraZeneca received the U.S. Food and Drug Administration for its FASENRA (benralizumab), in the form of a pre-filled, single-use auto-injector (the FASENRA Pen) indicated for the treatment of severe eosinophilic asthma

Moreover, small companies are focused on the development of novel epinephrine auto injectors, which offer thermal stability. Currently available products work optimally at specific temperatures, thereby providing a growth opportunity for manufacturers in the global subcutaneous drug delivery market. For instance, Windgap Medical is focused on developing a portable device that would mix a dry formulation of the drug into solution, thus providing temperature stability and a longer shelf-life of medication, for patients suffering from anaphylaxis due to an acute allergy attack.

Convenience and safety for both patients and medical professionals offered by these devices are also major factors leading to growth of the global subcutaneous drug delivery market. According to the World Health Organization, 2014, around 2 million healthcare professionals, globally, suffer from infectious diseases as result of needlestick injuries. The retractable nature of prefilled syringes help to overcome this problem, thereby acting as an ideal device to reduce the occurrence of needlestick injuries.

(Read more…)

Among region, Asia Pacific is expected to witness high growth during the forecast period due to rising geriatric population and the increasing incidence of chronic diseases such as diabetes, which is expected to drive growth of the subcutaneous drug delivery market in this region.

Request for Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/2933

Key Market Takeaways:

The global subcutaneous drug delivery market is expected to exhibit a CAGR of 9.7% over the forecast period, owing to increasing product launches. In January 2019, Sandoz Inc., a division of Novartis International AG, launched SYMJEPI (epinephrine) 0.3 mg single-dose, pre-filled syringe for emergency treatment of (Type 1) allergic reactions including anaphylaxis.

Local manufacturers in Europe such as Bausch & Lomb have developed Emerade, an adrenaline auto-injector and the product is distributed in Sweden, Norway, Denmark, Finland, the Netherlands, the U.K., Ireland, Czech Republic, and Germany. This is expected to be a factor driving growth of the market in the region.

Competitive Landscape:

Key players operating in the global subcutaneous drug delivery market include Becton Dickinson and Company, Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Novartis International AG, Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Consort Medical plc, Eli Lilly and Company, and Merck & Co., Inc., Novartis International AG, Insulet Corporation, West Pharmaceutical Services, Inc., and Gerresheimer AG

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2933

Market Segmentation:

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. Our client base includes players from across various business verticals in over 57 countries worldwide.

Contacts

Mr. Shah

Senior Client Partner – Business Development

Coherent Market Insights

Phone:
US: +1-206-701-6702

UK: +44-020-8133-4027

Japan: +81-050-5539-1737

India: +91-848-285-0837

Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Exit mobile version